Fig. 5.

Presence of WFS1 mutation does not affect iPSC-derived OPCs/pmOLs differentiation. a Immunocytochemistry for O4 and MBP on OPCs/pmOLs generated from WS patient iPSC lines 1 and 2, with their respective isogenic controls. Scale bar: 100 μm. b-c Quantification of the number of immunostained O4⁺ (b) and MBP⁺ cells (c) present at DIV24. d RT-qPCR for oligodendroglia lineage markers OLIG1, OLIG2, and NKX2.2 throughout the OPC/pmOL differentiation of WS patient and isogenic lines. e Immunostaining for MBP on DIV24 oligodendroglia (23 days in vitro, DIV24) cultured on electrospinning fibers for two weeks. Scale bar: 25 μm. Unpaired t-test; t₄ = 1.840 for WS patient 1 vs. isogenic 1 and t₄ = 1.268 for WS patient 2 vs. isogenic 2, for O4; t₄ = 1.406 for WS patient 1 vs. isogenic 1 and t₄ = 1.062 for WS patient 2 vs. isogenic 2, for MBP. Data presented as mean ± SEM, n = 3 (a, c,d), n = 1 (e) and n = 3 (f)